Drug Profile
Research programme: vascular endothelial growth factor receptor 3 antagonists - Sareum
Alternative Names: Research programme: FLT4 antagonists - SareumLatest Information Update: 28 Jul 2016
Price :
$50
*
At a glance
- Originator Sareum
- Class Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2016 No reports on development identified - Preclinical for Cancer in United Kingdom (PO)
- 09 Dec 2010 Research programme: vascular endothelial growth factor receptor 3 antagonists - Sareum is available for licensing as of 09 Dec 2010. http://www.sareum.co.uk
- 15 Feb 2010 Preclinical development is ongoing in UK